{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"100"},{"groupId":"OG002","value":"100"},{"groupId":"OG003","value":"100"},{"groupId":"OG004","value":"100"},{"groupId":"OG005","value":"100"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"6"}],"units":"Participants"}],"description":"An adverse event is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution.","groups":[{"description":"One participant was assigned to receive intermittent cobimetinib 80 milligrams (mg) + GDC 0994 200 mg) and did receive study drug. However, the participant diary was not returned, and the site was unable to document study dose administration.","id":"OG000","title":"Not Assigned"},{"description":"Concurrent or intermittent dosing of cobimetinib 20 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.","id":"OG001","title":"COB 20 mg + GDC 200 mg"},{"description":"Concurrent or intermittent dosing of cobimetinib 40 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.","id":"OG002","title":"COB 40 mg + GDC 200 mg"},{"description":"Concurrent or intermittent dosing of cobimetinib 80 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.","id":"OG003","title":"COB 80 mg + GDC 200 mg"},{"description":"Concurrent or intermittent dosing of cobimetinib 80 mg, concurrent with GDC-0994 400 mg for 21 consecutive days, followed by 7 days off.","id":"OG004","title":"COB 80 mg + GDC 400 mg"},{"description":"Concurrent or intermittent dosing of cobimetinib 100 mg, concurrent with GDC-0994 200 mg for 21 consecutive days, followed by 7 days off.","id":"OG005","title":"COB 100 mg + GDC 200 mg"}],"paramType":"NUMBER","populationDescription":"All participants.","reportingStatus":"POSTED","timeFrame":"Up to 15 months","title":"Percentage of Participants With at Least One Adverse Event","type":"PRIMARY","unitOfMeasure":"percentage of participants"}